[ad_1]
Bragar Eagel & Squire, PC is a nationally recognized shareholder rights law firm that is investigating against Ocugen, Inc. (NASDAQ:OCGN) On behalf of Ocugen shareholders. Our investigation involved whether Ocugen violated federal securities laws and/or engaged in other illegal business practices.
Click on Here Participate in the action.
On May 26, 2021, Ocugen announced that it plans to submit an emergency use authorization (“EUA”) application for the COVID-19 vaccine COVAXIN to the FDA in June 2021. On June 10, 2021, Ocugen announced that it “will no longer seek emergency use authorization (EUA) for COVAXIN,” but instead choose to “submit a biologics license application (BLA) for its COVID-19 vaccine candidate COVAXIN.” The Chairman and CEO of Ocugen stated: “Although we are about to complete the EUA submission application, we have received advice from the FDA to seek the BLA route, and this will extend our timeline. ”
According to this news, Ocugen’s stock price fell by more than 24% in intraday trading on the same day.
On June 10, 2021, the company stated that it will no longer seek EUA for Covaxin, but instead aims to apply for the full US approval of the vaccine.
Affected by this news, the stock price plummeted, closing at $6.69 per share on June 11, 2021, a drop of 25.17% from the closing price of $9.31 per share on June 10, 2021.
If you have purchased or otherwise acquired Ocugen stock and suffered losses, are a long-term shareholder, have information, want to learn more about these claims, or have any questions about this announcement or your rights or interests in these matters, please pass Contact Brandon Walker, Melissa Fortunato or Marion Passmore by email Investigate @bespc.com, Call (212) 355-4648, or pass Fill out this contact form. You do not have to bear any costs or obligations.
About Bragar Eagel & Squire, PC:
Bragar Eagel & Squire, PC is a nationally renowned law firm with offices in New York, California and South Carolina. The company represents individual and institutional investors in commercial, securities, derivatives, and other complex litigations in state and federal courts across the country.For more information about the company, please visit www.bespc.com. Attorney ads. The previous results do not guarantee similar results.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20210611005500/en/
[ad_2]
Source link
